CCND1 and prostate adenocarcinoma: Other commonly observed genomic alterations in NEPCs include the copy number amplification and overexpression of genes, such as Aurora kinase A (AURKA), Neuroblastoma-derived MYC (MYCN), Enhancer of Zeste homolog 2 (EZH2), and Cyclin D1 (CCND1), UBE2C, NTS, MDK, NPPB, NTSR1, RB1, FOXA2, REST, and SRRM4 relative to prostate adenocarcinoma [283,284,285,286].